Biosimilar medicines have delivered 18BN€ total savings for Europe but more action needed to translate this potential into patient access and sustainable health

15 December 2021

Commission study highlights market framework conditions are main driver for medicines shortages

9 December 2021

REGULATORY FOCUS – New reports address generics pricing, innovation in the EU

2 December 2021

Open

Access to essential medicines threatened by combination of increasing inflation and potential further price cuts in EU countries

26 November 2021

European Parliament report calls for increased use of off-patent medicines to improve patient access

24 November 2021

The EU must stop the offshoring of essential medicines manufacturing investments

23 November 2021

Open letter: Urgent call to amend the Temporary State Aid Framework to achieve the Recovery and Resiliency Facility objectives

17 November 2021

Adjustments to IP framework needed to improve access to medicines in Europe

16 November 2021

Access to generic and biosimilar medicines can be improved with coherent proposals for IP […]

Margaritis Schinas and Adrian Van Den Hoven visited ELPEN

15 November 2021

Access to medicines critical in European Parliament vote on EU IP action plan

12 November 2021

The European Parliament Own Initiative Report on an intellectual property […]